Neurocrine (NBIX) executive sells 3,888 shares in pre-set 10b5-1 trade

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES INC Chief Corp. Affairs Officer David W. Boyer reported an open-market sale of 3,888 shares of common stock. The shares were sold at a weighted average price of $156.6418 per share in multiple trades between $155.81 and $157.62.

The transaction was executed by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 23, 2026, which the company’s policy does not allow him to amend after adoption. Following this sale, Boyer directly holds 7,799 shares, including 106 shares acquired through the company’s 2018 Employee Stock Purchase Plan.

Insider Trade Summary 10b5-1

Net Seller: 3,888 shares ($609,023)

Net Sell 1 txn

Insider Boyer David W.

Role Chief Corp. Affairs Officer

Sold 3,888 shs ($609K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,888	$156.6418	$609K

Holdings After Transaction: Common Stock — 7,799 shares (Direct, null)

Footnotes (1)

1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.81 to $157.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Includes an aggregate of 106 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

Key Figures

Shares sold: 3,888 shares Weighted average sale price: $156.6418 per share Sale price range: $155.81–$157.62 per share +3 more

6 metrics

Shares sold 3,888 shares Open-market sale on May 26, 2026

Weighted average sale price $156.6418 per share Common stock sale

Sale price range $155.81–$157.62 per share Multiple transactions during the sale

Shares owned after transaction 7,799 shares Direct holdings following the sale

ESPP shares included 106 shares Purchased February 27, 2026 under 2018 Employee Stock Purchase Plan

Net shares sold 3,888 shares Net-sell direction in transaction summary

Key Terms

Rule 10b5-1 trading plan, weighted average sales price, Employee Stock Purchase Plan

3 terms

Rule 10b5-1 trading plan regulatory

"instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sales price financial

"Represents a weighted average sales price per share. These shares were sold in multiple transactions"

Employee Stock Purchase Plan financial

"purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boyer David W.

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Corp. Affairs Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/26/2026		S(1)		3,888	D	$156.6418(2)	7,799(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.81 to $157.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. Includes an aggregate of 106 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did NBIX executive David Boyer report?

David W. Boyer reported selling 3,888 shares of Neurocrine Biosciences common stock. The sale was an open-market transaction executed by a broker under a pre-arranged Rule 10b5-1 trading plan, as disclosed in the filing’s footnotes.

At what prices did David Boyer sell NBIX shares in this Form 4?

The filing states a weighted average sale price of $156.6418 per share. Shares were sold in multiple transactions at prices ranging from $155.81 to $157.62, with detailed trade breakdowns available from the company or SEC staff on request.

Was the NBIX insider sale by David Boyer made under a Rule 10b5-1 plan?

Yes, the sale was carried out pursuant to a Rule 10b5-1 trading plan adopted on February 23, 2026. Company policy also restricts Boyer from amending or modifying any such trading plan after its adoption, indicating the sale was pre-scheduled.

How many NBIX shares does David Boyer hold after this reported sale?

After the reported sale, David W. Boyer directly owns 7,799 shares of Neurocrine Biosciences common stock. This total includes 106 shares purchased through the company’s 2018 Employee Stock Purchase Plan, as specifically noted in the footnotes.

What role does David Boyer hold at Neurocrine Biosciences (NBIX)?

David W. Boyer is identified as an officer of Neurocrine Biosciences, serving as Chief Corporate Affairs Officer. His position and insider status require reporting transactions in company stock on Form 4, including this recent open-market sale of common shares.